Aurora Cannabis Reaffirms Growth Guidance and Expands International Footprint

Key Facts

1Aurora Cannabis reaffirmed its FY2027 Q2 guidance for sequential growth in net revenue and adjusted EBITDA.

2The acquisition of Safari Flower Company is expected to contribute incremental revenue following its EU-GMP certification.

3The company continues its European expansion with strong performance in Germany and Poland and targeted growth in the UK.

Amid a strategic push to solidify leadership in the global medical cannabis sector, Aurora Cannabis has reaffirmed its financial guidance for the second quarter of fiscal year 2027. The company anticipates sequential growth in both net revenue and adjusted EBITDA, signaling a robust trajectory for its core operations and international business segments.

A key driver of this outlook is the integration of the Safari Flower Company, which is expected to generate incremental revenue following its EU-GMP certification. Per market data and company reports, Aurora is maintaining a strong performance in high-margin European markets such as Germany and Poland, while targeting further expansion in the UK through its acquisitions of Internode Pharma and HAP Pharma Limited.

In the equity markets, ACB shares stood at $3.82 at close on September 15, 2026, after trading within a daily range of $3.74 to $3.84. Investors should monitor regional economic stability as a catalyst for growth; recent data shows interest rates in Poland held steady at 3.75% on September 9, 2026, supporting the company's capital-intensive expansion efforts in the European region.